Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.83 USD | +5.06% | -40.71% | +19.94% |
May. 14 | Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target | MT |
May. 09 | Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 19.81M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.76
x | P/E ratio 2025 * |
-0.74
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.52% |
1 day | +5.06% | ||
1 week | -40.71% | ||
Current month | -18.62% | ||
1 month | -18.63% | ||
3 months | -1.19% | ||
6 months | +27.69% | ||
Current year | +19.94% |
Managers | Title | Age | Since |
---|---|---|---|
John Celebi
CEO | Chief Executive Officer | 52 | 18-01-31 |
Erin Colgan
DFI | Director of Finance/CFO | 43 | 20-06-30 |
Chief Tech/Sci/R&D Officer | 51 | 19-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Ringo
CHM | Chairman | 78 | 22-03-07 |
John Celebi
CEO | Chief Executive Officer | 52 | 18-01-31 |
Bob Holmen
BRD | Director/Board Member | 60 | 16-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 0.83 | +5.06% | 789,724 |
24-05-24 | 0.79 | -45.52% | 1,408,115 |
24-05-23 | 1.45 | +6.62% | 875,187 |
24-05-22 | 1.36 | -2.86% | 162,025 |
24-05-21 | 1.4 | -6.67% | 192,396 |
Delayed Quote Nasdaq, May 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.94% | 19.81M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- SNSE Stock